Kitching AR, Anders H-J, Basu N, Brouwer E, Gordon J, Jayne DR, et al. ANCA-associated vasculitis. Nat Rev Dis Primer. 2020;6:71. https://doi.org/10.1038/s41572-020-0204-y.

Article  Google Scholar 

U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) v5.0 [Internet]. 2017 [cited 2024 Mar 30]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.

Rathmann J, Jayne D, Segelmark M, Jönsson G, Mohammad AJ. Incidence and predictors of severe infections in ANCA-associated vasculitis: a population-based cohort study. Rheumatol Oxf Engl. 2021;60:2745–54. https://doi.org/10.1093/rheumatology/keaa699.

Article  Google Scholar 

Thomas K, Argyriou E, Kapsala N, Panagiotopoulos A, Chalkia A, Hadziyannis E, et al. Serious infections in ANCA-associated vasculitides in the biologic era: real-life data from a multicenter cohort of 162 patients. Arthritis Res Ther. 2021;23:90. https://doi.org/10.1186/s13075-021-02452-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Therkildsen P, de Thurah A, Nielsen BD, Faurschou M, Baslund B, Hansen IT, et al. The one-year infection risk among patients diagnosed with giant cell arteritis: use of antibiotics and hospitalisations. Rheumatol Oxf Engl. 2024:keae107. https://doi.org/10.1093/rheumatology/keae107.

Monti S, Milanesi A, Klersy C, Tomelleri A, Dagna L, Campochiaro C, et al. Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients. Ann Rheum Dis. 2023;82:1098–106. https://doi.org/10.1136/ard-2023-223895.

Article  PubMed  Google Scholar 

. Tedeschi SK, Jin Y, Vine S, Lee H, Pethoe-Schramm A, Yau V, et al. Giant cell arteritis treatment patterns and rates of serious infections. Clin Exp Rheumatol. 2022;40:826–33. https://doi.org/10.55563/clinexprheumatol/uonz1p. Large national analysis of treatment patterns and infection in individuals with GCA.

Article  PubMed  Google Scholar 

Singh JA, Cleveland JD. Serious infections in people with polymyalgia rheumatica (PMR) or giant cell arteritis (GCA): a time-trend national US study. Clin Rheumatol. 2020;39:3427–38. https://doi.org/10.1007/s10067-020-05129-w.

Article  PubMed  Google Scholar 

Nossent J, Raymond W, Isobel Keen H, Preen D, Inderjeeth C. Morbidity and mortality in adult-onset IgA vasculitis: a long-term population-based cohort study. Rheumatol Oxf Engl. 2021;61:291–8. https://doi.org/10.1093/rheumatology/keab312.

Article  Google Scholar 

Caillard P, Vigneau C, Halimi J-M, Hazzan M, Thervet E, Heitz M, et al. Severe Infection in Anti-Glomerular Basement Membrane Disease: A Retrospective Multicenter French Study. J Clin Med. 2020;9:698. https://doi.org/10.3390/jcm9030698.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vassilopoulos A, Vassilopoulos S, Kalligeros M, Shehadeh F, Mylonakis E. Incidence of serious infections in patients with ANCA-associated vasculitis receiving immunosuppressive therapy: A systematic review and meta-analysis. Front Med. 2023;10:1110548. https://doi.org/10.3389/fmed.2023.1110548.

Article  Google Scholar 

Steinberg AW, Wechsler ME, Fernández Pérez ER. Trends in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis-Related Mortality in the United States, 1999 to 2017. Ann Intern Med. 2020;172:160–3. https://doi.org/10.7326/m19-1564.

Article  PubMed  Google Scholar 

Wallace ZS, Fu X, Harkness T, Stone JH, Zhang Y, Choi H. All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type. Rheumatol Oxf Engl. 2020;59:2308–15. https://doi.org/10.1093/rheumatology/kez589.

Article  CAS  Google Scholar 

Shuai Z-Q, Zhang C-X, Shuai Z-W, Ge S-L. Efficacy and safety of biological agents in the treatment of patients with Takayasu arteritis: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2021;25:250–62. https://doi.org/10.26355/eurrev_202101_24391.

Article  PubMed  Google Scholar 

World Health Organization. Global tuberculosis report 2022 [Internet]. Geneva: World Health Organization; 2022. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022

Google Scholar 

Li L, Zhou F, Li F, Chen J, Xie X. Prevalence of tuberculosis infection among patients with Takayasu arteritis: a meta-analysis of observational studies. Sci Rep. 2023;13:22481. https://doi.org/10.1038/s41598-023-49998-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

England BR, Sayles H, Mikuls TR, Johnson DS, Michaud K. Validation of the rheumatic disease comorbidity index. Arthritis Care Res. 2015;67:865–72. https://doi.org/10.1002/acr.22456.

Article  Google Scholar 

Thietart S, Karras A, Augusto J-F, Philipponnet C, Carron P-L, Delbrel X, et al. Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. JAMA Netw Open. 2022;5:e2220925. https://doi.org/10.1001/jamanetworkopen.2022.20925.

Article  PubMed  PubMed Central  Google Scholar 

Bloom JL, Pickett-Nairn K, Silveira L, Fuhlbrigge RC, Cuthbertson D, Akuthota P, et al. The Association Between Age at Diagnosis and Disease Characteristics and Damage in Patients With ANCA-Associated Vasculitis. Arthritis Rheumatol Hoboken NJ. 2023;75:2216–27. https://doi.org/10.1002/art.42651.

Article  CAS  Google Scholar 

Osman M, Pagnoux C, Dryden DM, Storie D, Yacyshyn E. The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis. PloS One. 2014;9:e115026. https://doi.org/10.1371/journal.pone.0115026.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bandeen-Roche K, Seplaki CL, Huang J, Buta B, Kalyani RR, Varadhan R, et al. Frailty in Older Adults: A Nationally Representative Profile in the United States. J Gerontol A Biol Sci Med Sci. 2015;70:1427–34. https://doi.org/10.1093/gerona/glv133.

Article  PubMed  PubMed Central  Google Scholar 

Sattui S, Fu X, Cook C, Srivatsan S, Zhang Y, Wallace Z. The Impact of Chronologic versus Biologic Age on the Risk of Severe Infection, End-Stage Renal Disease, and Death in Older Adults with ANCA-Associated Vasculitis. In: ACR Meet Abstr [Internet]. San Diego, CA; 2023. Available from: https://acrabstracts.org/abstract/the-impact-of-chronologic-versus-biologic-age-on-the-risk-of-severe-infection-end-stage-renal-disease-and-death-in-older-adults-with-anca-associated-vasculitis/.

Sattui S, Stadler J, Borchin R, Burroughs C, Yeung C, Merkel P, et al. The Association of Frailty with Outcomes in Patients with Vasculitis. In: ACR Meet Abstr [Internet]. San Diego, CA; 2023. Available from: https://acrabstracts.org/abstract/the-association-of-frailty-with-outcomes-in-patients-with-vasculitis/.

Uslu Yurteri E, Sezer S, Torgutalp M, Yayla ME, Sahin Eroglu D, Okatan IE, et al. The factors predicting development of serious infections in ANCA-associated vasculitis. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG. 2023;40:e2023015. https://doi.org/10.36141/svdld.v40i2.13243.

Article  Google Scholar 

Kronbichler A, Kerschbaum J, Gopaluni S, Tieu J, Alberici F, Jones RB, et al. Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2018;77:1440–7. https://doi.org/10.1136/annrheumdis-2017-212861.

Article  CAS  PubMed  Google Scholar 

Haris Á, Polner K, Arányi J, Braunitzer H, Kaszás I. Incidence and clinical predictors of infections in patients treated with severe systemic ANCA-associated vasculitis. Physiol Int. 2021; https://doi.org/10.1556/2060.2021.00006.

Sarica SH, Gallacher PJ, Dhaun N, Sznajd J, Harvie J, McLaren J, et al. Multimorbidity in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results From a Longitudinal, Multicenter Data Linkage Study. Arthritis Rheumatol Hoboken NJ. 2021;73:651–9. https://doi.org/10.1002/art.41557.

Article  CAS  Google Scholar 

. Furuta S, Nakagomi D, Kobayashi Y, Hiraguri M, Sugiyama T, Amano K, et al. Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial. JAMA. 2021;325:2178–87. https://doi.org/10.1001/jama.2021.6615. RCT comparing standard vs low-dose glucocorticoid regimens in AAV showing lower risk of incident infections.

Article  CAS  PubMed  Google Scholar 

. Walsh M, Merkel PA, Peh C-A, Szpirt WM, Puéchal X, Fujimoto S, et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med. 2020;382:622–31. https://doi.org/10.1056/nejmoa1803537. RCT showing lower risk of incident infections and similar outcomes with low-dose glucocorticoid regimen in individuals with severe AAV.

Article  CAS  PubMed  PubMed Central  Google Scholar 

DRW J, Merkel PA, Schall TJ, Bekker P, ADVOCATE Study Group. Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med. 2021;384:599–609. https://doi.org/10.1056/nejmoa2023386.

Article  CAS  Google Scholar 

Nagle S, Nguyen Y, Puéchal X, Titeca-Beauport D, Crépin T, Mesbah R, et al. Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis. In: ACR Meet Abstr [Internet]. San Diego, CA; 2023. Available from: https://acrabstracts.org/abstract/real-life-use-of-the-pexivas-reduced-dose-glucocorticoid-regimen-in-granulomatosis-with-polyangiitis-and-microscopic-polyangiitis/.

Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024;83:30–47. https://doi.org/10.1136/ard-2022-223764.

Article  PubMed  Google Scholar 

Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care Res. 2021;73:1088–105. https://doi.org/10.1002/acr.24634.

Article  Google Scholar 

. Thery-Casari C, Euvrard R, Mainbourg S, Durupt S, Reynaud Q, Durieu I, et al. Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A meta-analysis. Autoimmun Rev. 2020;19:102505. https://doi.org/10.1016/j.autrev.2020.102505. Meta-analysis analyzing incidence of severe infections and risk factors in individuals with AAV receiving treatment with rituximab.

Article  CAS  PubMed  Google Scholar 

. Odler B, Riedl R, Gauckler P, Shin JI, Leierer J, Merkel PA, et al. Risk factors for serious infections in ANCA-associated vasculitis. Ann Rheum Dis. 2023;82:681–7. https://doi.org/10.1136/ard-2022-223401. Post-hoc analysis of RAVE study showing decreased risk of infections associated to use of antibiotic prophylaxis.

Article  CAS  PubMed  Google Scholar 

Md Yusof MY, Vital EM, McElvenny DM, Hensor EMA, Das S, Dass S, et al. Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol Hoboken NJ. 2019;71:1812–23. https://doi.org/10.1002/art.40937.

Article  CAS  Google Scholar 

Habibi MA, Alesaeidi S, Zahedi M, Hakimi Rahmani S, Piri SM, Tavakolpour S. The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review. Biology. 2022;11:1767. https://doi.org/10.3390/biology11121767.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, et al. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun. 2015;57:60–5. https://doi.org/10.1016/j.jaut.2014.11.009.